574007-62-8

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester, (2R,6R)-
• Synonyms: 1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester, (2R,6R)-;(2R,6R)-tert-Butyl 2,6-diMethylpiperazine-1-carboxylate;tert-Butyl (2R,6R)-2,6-diMethylpiperazine-1-carboxylate;(2R,6R)-2,6-Dimethyl-1-piperazinecarboxylic acid 1,1-dimethylethyl ester;(2R,6R)-1-Boc-2,6-dimethyl-piperazine
• CAS NO: 574007-62-8
• Molecular Formula: C11H22N2O2
• Molecular Weight: 214.30458
• Mol File: 574007-62-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 279.7°C at 760 mmHg
• Flash Point: 123°C
• Appearance: /
• Density: 0.97g/cm³
• Vapor Pressure: 0.00394mmHg at 25°C
• Refractive Index: 1.452
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.53±0.60(Predicted)
• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester, (2R,6R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester, (2R,6R)-(574007-62-8)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester, (2R,6R)-(574007-62-8)

Safety Data

• Hazardous Substances Data: 574007-62-8(Hazardous Substances Data)

Usage

General Description

1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester, (2R,6R)-, also known as Quetiapine Fumarate, is a psychiatric medication used to treat conditions such as schizophrenia, bipolar disorder, and major depressive disorder. It works by restoring the balance of certain natural substances in the brain. It is classified as an atypical antipsychotic and functions by blocking the activity of dopamine and serotonin in the brain. Quetiapine Fumarate is available in tablet form and is typically taken orally, with dosage depending on the specific condition being treated. Common side effects may include dizziness, drowsiness, and weight gain, but serious side effects such as high blood sugar and neuroleptic malignant syndrome are also possible.

InChI:InChI=1/C11H22N2O2/c1-8-6-12-7-9(2)13(8)10(14)15-11(3,4)5/h8-9,12H,6-7H2,1-5H3/t8-,9-/m1/s1

Upstream product

• 623585-97-7 benzyl (3S,5R)-3,5-dimethylpiperazine-1-carboxylate 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 2080367-38-8 4-benzyl 1-(tert-butyl) (2R,6S)-2,6-dimethylpiperazine-1,4-dicarboxylate 
• 1207455-37-5 benzyl 4-(t-butoxycarbonyl)-3,5-dimethylpiperazine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 108-49-6 3,5-dimethylpiperazine 

Downstream Products

• 1610520-52-9 tert-butyl 4-((7-(3,4-dimethoxyphenyl)-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridin-2-yl)methyl)-2,6-dimethylpiperazine-1-carboxylate 

Relevant articles and documents

JAK1 SELECTIVE INHIBITORS

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.